Paul Aisen, MD

Paul Aisen, M.D., has been appointed founding director of USC ATRI. Aisen has been a leading figure in Alzheimer’s disease research for more than two decades, having developed novel methodologies as well as designed and directed many large therapeutic trials. He received his B.A. in biochemistry and molecular biology from Harvard and his medical degree from Columbia. He completed his residency at Case Western Reserve University in Cleveland and Mount Sinai Medical Center in New York, and then fellowship training in rheumatology at New York University. After serving as chief medical resident at Mount Sinai, he began a solo practice in internal medicine and rheumatology in New York. Aisen joined the faculty of Mount Sinai in 1994 and was recruited to Georgetown University in 1999 as a professor of neurology and medicine. That year, he founded the Memory Disorders Program, a clinical and research program for Alzheimer’s disease and related disorders. He continued basic research studies on therapeutic targets and biomarkers and designed and directed multicenter therapeutic trials. He became vice chair of the Department of Neurology at Georgetown in 2004. From 2007 through 2015, he was professor in the Department of Neurosciences at the University of California, San Diego and director of the Alzheimer’s Disease Cooperative Study.

• The case for regulatory approval of amyloid-lowering immunotherapies in Alzheimer’s disease based on clearcut biomarker evidence Alzheimers Dement. 2024 Nov 13. . View in PubMed
• Cortico-limbic volume abnormalities in late life depression are distinct from ß amyloid and white matter pathologies Mol Psychiatry. 2024 Nov 07. . View in PubMed
• The ADNI4 Digital Study: A novel approach to recruitment, screening, and assessment of participants for AD clinical research Alzheimers Dement. 2024 Oct; 20(10):7232-7247. . View in PubMed
• The Alzheimer’s Disease Neuroimaging Initiative Clinical Core Alzheimers Dement. 2024 Oct; 20(10):7361-7368. . View in PubMed
• Benefits and risks of FDA-approved amyloid-targeting antibodies for treatment of early Alzheimer’s disease: Navigating clinician-patient engagement Alzheimers Dement. 2024 Sep 22. . View in PubMed
• CYP1B1-RMDN2 Alzheimer’s disease endophenotype locus identified for cerebral tau PET Nat Commun. 2024 Sep 20; 15(1):8251. . View in PubMed
• Anxiety in late-life depression is associated with poorer performance across multiple cognitive domains J Int Neuropsychol Soc. 2024 Sep 18; 1-5. . View in PubMed
• A Protocol for the Inclusion of Minoritized Persons in Alzheimer Disease Research From the ADNI3 Diversity Taskforce JAMA Netw Open. 2024 Aug 01; 7(8):e2427073. . View in PubMed
• Immediate Reactions to Alzheimer Biomarker Disclosure in Cognitively Unimpaired Individuals in a Global Truncated Randomized Trial Neurol Clin Pract. 2024 Apr; 14(2):e200265. . View in PubMed
• Eligibility Rates among Racially and Ethnically Diverse US Participants in Phase 2 and Phase 3 Placebo-Controlled, Double-Blind, Randomized Trials of Lecanemab and Elenbecestat in Early Alzheimer Disease Ann Neurol. 2024 Feb; 95(2):288-298. . View in PubMed
• Anxiety in late-life depression: Associations with brain volume, amyloid beta, white matter lesions, cognition, and functional ability Int Psychogeriatr. 2024 Jan 25; 1-12. . View in PubMed
• Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimer’s disease trial Alzheimers Dement. 2024 06; 20(6):3827-3838. . View in PubMed
• Relationship of Hoarding and Depression Symptoms in Older Adults Am J Geriatr Psychiatry. 2024 04; 32(4):497-508. . View in PubMed
• Plasma Aß42/Aß40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer’s disease Alzheimers Dement. 2024 02; 20(2):1214-1224. . View in PubMed
• The Alzheimer’s Disease Neuroimaging Initiative in the era of Alzheimer’s disease treatment: A review of ADNI studies from 2021 to 2022 Alzheimers Dement. 2024 01; 20(1):652-694. . View in PubMed
• Views and Perceptions of Amyloid Imaging in a Preclinical Alzheimer’s Disease Trial J Prev Alzheimers Dis. 2024; 11(6):1563-1571. . View in PubMed
• A Statistical Framework for Assessing the Relationship between Biomarkers and Clinical Endpoints in Alzheimer’s Disease J Prev Alzheimers Dis. 2024; 11(5):1228-1240. . View in PubMed
• Clinical Meaningfulness in Alzheimer’s Disease Clinical TrialsA Report from the EU-US CTAD Task Force. J Prev Alzheimers Dis. 2024; 11(5):1219-1227. . View in PubMed
• The AlzMatch Pilot Study – Feasibility of Remote Blood Collection of Plasma Biomarkers for Preclinical Alzheimer’s Disease Trials J Prev Alzheimers Dis. 2024; 11(5):1435-1444. . View in PubMed
• Estimating Socio-Economic Status for Alzheimer’s Disease Trials J Prev Alzheimers Dis. 2024; 11(5):1418-1425. . View in PubMed
• Longitudinal Trajectories of the Cognitive Function Index in the A4 Study J Prev Alzheimers Dis. 2024; 11(4):838-845. . View in PubMed
• Maximizing the Utility of Alzheimer’s Disease Trial Data: Sharing of Baseline A4 and LEARN Data J Prev Alzheimers Dis. 2024; 11(4):889-894. . View in PubMed
• Change in Digital Cognitive Test Performance between Solanezumab and Placebo Groups in Preclinical Alzheimer’s Disease: Secondary Analyses from the A4 Study J Prev Alzheimers Dis. 2024; 11(4):846-856. . View in PubMed
• Editorial: Introduction to the Special Issue on the A4 Study J Prev Alzheimers Dis. 2024; 11(4):801. . View in PubMed
• Greater White Matter Hyperintensity Volume Is Associated with the Number of Microhemorrhages in Preclinical Alzheimer’s Disease J Prev Alzheimers Dis. 2024; 11(4):869-873. . View in PubMed
• Longitudinal Phospho-tau217 Predicts Amyloid Positron Emission Tomography in Asymptomatic Alzheimer’s Disease J Prev Alzheimers Dis. 2024; 11(4):823-830. . View in PubMed
• Characterizing Clinical Progression in Cognitively Unimpaired Older Individuals with Brain Amyloid: Results from the A4 Study J Prev Alzheimers Dis. 2024; 11(4):814-822. . View in PubMed
• Pre-Randomization Predictors of Study Discontinuation in a Preclinical Alzheimer’s Disease Randomized Controlled Trial J Prev Alzheimers Dis. 2024; 11(4):874-880. . View in PubMed
• Safety Profile of a Cognitively Unimpaired Older Population with Elevated Cerebral Amyloid in a 45-Year Clinical Trial. J Prev Alzheimers Dis. 2024; 11(4):857-868. . View in PubMed
• Amyloid and Tau Prediction of Cognitive and Functional Decline in Unimpaired Older Individuals: Longitudinal Data from the A4 and LEARN Studies J Prev Alzheimers Dis. 2024; 11(4):802-813. . View in PubMed
• Relationship between Plasma P-Tau217 and Amyloid PET in Racial and Ethnic Underrepresented Groups (RE-URG) Compared with Non RE-URG in LEARN and A4 J Prev Alzheimers Dis. 2024; 11(4):831-837. . View in PubMed
• A Pragmatic, Investigator-Driven Process for Disclosure of Amyloid PET Scan Results to ADNI-4 Research Participants J Prev Alzheimers Dis. 2024; 11(2):294-302. . View in PubMed
• Trial of Solanezumab in Preclinical Alzheimer’s Disease N Engl J Med. 2023 Sep 21; 389(12):1096-1107. . View in PubMed
• Natural cubic splines for the analysis of Alzheimer’s clinical trials Pharm Stat. 2023 May-Jun; 22(3):508-519. . View in PubMed
• Safety and tolerability of lumbar puncture for the evaluation of Alzheimer’s disease Alzheimers Dement (Amst). 2023 Apr-Jun; 15(2):e12431. . View in PubMed
• Novel CYP1B1-RMDN2 Alzheimer’s disease locus identified by genome-wide association analysis of cerebral tau deposition on PET medRxiv. 2023 Mar 22. . View in PubMed
• Learning slopes in early-onset Alzheimer’s disease Alzheimers Dement. 2023 11; 19 Suppl 9:S19-S28. . View in PubMed
• The Sporadic Early-onset Alzheimer’s Disease Signature Of Atrophy: Preliminary Findings From The Longitudinal Early-onset Alzheimer’s Disease Study (LEADS) Cohort Alzheimers Dement. 2023 11; 19 Suppl 9:S74-S88. . View in PubMed
• Baseline neuropsychiatric symptoms and psychotropic medication use midway through data collection of the Longitudinal Early-Onset Alzheimer’s Disease Study (LEADS) cohort Alzheimers Dement. 2023 11; 19 Suppl 9:S42-S48. . View in PubMed
• White matter hyperintensities are higher among early-onset Alzheimer’s disease participants than their cognitively normal and early-onset nonAD peers: Longitudinal Early-onset Alzheimer’s Disease Study (LEADS) Alzheimers Dement. 2023 11; 19 Suppl 9:S89-S97. . View in PubMed
• Cerebrospinal fluid biomarkers in the Longitudinal Early-onset Alzheimer’s Disease Study Alzheimers Dement. 2023 11; 19 Suppl 9:S115-S125. . View in PubMed
• Pathogenic variants in the Longitudinal Early-onset Alzheimer’s Disease Study cohort Alzheimers Dement. 2023 11; 19 Suppl 9:S64-S73. . View in PubMed
• Amyloid and tau-PET in early-onset AD: Baseline data from the Longitudinal Early-onset Alzheimer’s Disease Study (LEADS) Alzheimers Dement. 2023 11; 19 Suppl 9:S98-S114. . View in PubMed
• Profiling baseline performance on the Longitudinal Early-Onset Alzheimer’s Disease Study (LEADS) cohort near the midpoint of data collection Alzheimers Dement. 2023 11; 19 Suppl 9:S8-S18. . View in PubMed
• Influence of amyloid and diagnostic syndrome on non-traditional memory scores in early-onset Alzheimer’s disease Alzheimers Dement. 2023 11; 19 Suppl 9:S29-S41. . View in PubMed
• Sex and APOE e4 carrier effects on atrophy, amyloid PET, and tau PET burden in early-onset Alzheimer’s disease Alzheimers Dement. 2023 11; 19 Suppl 9:S49-S63. . View in PubMed
• The amyloid-ß pathway in Alzheimer’s disease: a plain language summary Neurodegener Dis Manag. 2023 06; 13(3):141-149. . View in PubMed
• Expectations and clinical meaningfulness of randomized controlled trials Alzheimers Dement. 2023 06; 19(6):2730-2736. . View in PubMed
• Detection and treatment of Alzheimer’s disease in its preclinical stage Nat Aging. 2023 05; 3(5):520-531. . View in PubMed
• Improving generalizability and study design of Alzheimer’s disease cohort studies in the United States by including under-represented populations Alzheimers Dement. 2023 04; 19(4):1549-1557. . View in PubMed
• The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer’s disease Alzheimers Dement. 2023 04; 19(4):1227-1233. . View in PubMed
• Traumatic brain injury and post-traumatic stress disorder are not associated with Alzheimer’s disease pathology measured with biomarkers Alzheimers Dement. 2023 03; 19(3):884-895. . View in PubMed
• Recommendations to address key recruitment challenges of Alzheimer’s disease clinical trials Alzheimers Dement. 2023 02; 19(2):696-707. . View in PubMed
• Increasing participant diversity in AD research: Plans for digital screening, blood testing, and a community-engaged approach in the Alzheimer’s Disease Neuroimaging Initiative 4 Alzheimers Dement. 2023 01; 19(1):307-317. . View in PubMed
• J Prev Alzheimers Dis. 2023; 10(3):418-425. . View in PubMed
• Lecanemab in Early Alzheimer’s Disease N Engl J Med. 2023 01 05; 388(1):9-21. . View in PubMed
• Centralizing prescreening data collection to inform data-driven approaches to clinical trial recruitment Alzheimers Res Ther. 2023 05 02; 15(1):88. . View in PubMed
• Evaluation of Blood-Based Plasma Biomarkers as Potential Markers of Amyloid Burden in Preclinical Alzheimer’s Disease J Alzheimers Dis. 2023; 92(1):95-107. . View in PubMed
• Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab J Prev Alzheimers Dis. 2023; 10(2):171-177. . View in PubMed
• Tau positron emission tomography in preclinical Alzheimer’s disease Brain. 2023 02 13; 146(2):700-711. . View in PubMed
• Lecanemab: Appropriate Use Recommendations J Prev Alzheimers Dis. 2023; 10(3):362-377. . View in PubMed
• Corrigendum to: ATRI EDC: a novel cloud-native remote data capture system for large multicenter Alzheimer’s disease and Alzheimer’s disease-related dementias clinical trials JAMIA Open. 2022 Apr; 5(1):ooac008. . View in PubMed
• ATRI EDC: a novel cloud-native remote data capture system for large multicenter Alzheimer’s disease and Alzheimer’s disease-related dementias clinical trails JAMIA Open. 2022 Apr; 5(1):ooab119. . View in PubMed
• Randomised controlled trials for the prevention of cognitive decline or dementia: A systematic review Ageing Res Rev. 2022 12; 82:101777. . View in PubMed
• Screening and enrollment of underrepresented ethnocultural and educational populations in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Alzheimers Dement. 2022 12; 18(12):2603-2613. . View in PubMed
• The use of lumbar puncture and safety recommendations in Alzheimer’s disease: a plain language summary Neurodegener Dis Manag. 2022 10; 12(5):221-229. . View in PubMed
• Designing the next-generation clinical care pathway for Alzheimer’s disease Nat Aging. 2022 08; 2(8):692-703. . View in PubMed
• Contribution of Alzheimer’s biomarkers and risk factors to cognitive impairment and decline across the Alzheimer’s disease continuum Alzheimers Dement. 2022 07; 18(7):1370-1382. . View in PubMed
• Early-stage Alzheimer disease: getting trial-ready Nat Rev Neurol. 2022 07; 18(7):389-399. . View in PubMed
• Using the Alzheimer’s Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer’s disease Alzheimers Dement. 2022 04; 18(4):824-857. . View in PubMed
• State-of-the-art of lumbar puncture and its place in the journey of patients with Alzheimer’s disease Alzheimers Dement. 2022 01; 18(1):159-177. . View in PubMed
• Aducanumab: Appropriate Use Recommendations Update J Prev Alzheimers Dis. 2022; 9(2):221-230. . View in PubMed
• Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease J Prev Alzheimers Dis. 2022; 9(2):197-210. . View in PubMed
• Tackling a Major Deficiency of Diversity in Alzheimer’s Disease Therapeutic Trials: An CTAD Task Force Report J Prev Alzheimers Dis. 2022; 9(3):388-392. . View in PubMed
• Sensitivity of the Preclinical Alzheimer’s Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to Amyloid Status in Preclinical Alzheimer’s Disease -Atabecestat Phase 2b/3 EARLY Clinical Trial J Prev Alzheimers Dis. 2022; 9(2):255-261. . View in PubMed
• Non-Amyloid. Where Does Consensus Lie Today? An CTAD Task Force Report. J Prev Alzheimers Dis. 2022; 9(2):231-235. . View in PubMed
• Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease Alzheimers Res Ther. 2022 04 19; 14(1):54. . View in PubMed
• Associations of Stages of Objective Memory Impairment With Amyloid PET and Structural MRI: The A4 Study Neurology. 2022 03 29; 98(13):e1327-e1336. . View in PubMed
• Editorial: We Have Turned the Corner J Prev Alzheimers Dis. 2022; 9(S1):S5-S6. . View in PubMed
• Amyloid-Related Imaging Abnormalities and Other MRI Findings in a Cognitively Unimpaired Population With and Without Cerebral Amyloid J Prev Alzheimers Dis. 2022; 9(4):617-624. . View in PubMed
• J Prev Alzheimers Dis. 2022; 9(4):569-579. . View in PubMed
• Alzheimer’s Disease Clinical Trial Research Adaptation Following COVID-19 Pandemic Onset: National Sample of Alzheimer’s Clinical Trial Consortium Sites J Prev Alzheimers Dis. 2022; 9(4):665-671. . View in PubMed
• Impact of sex and APOE e4 on the association of cognition and hippocampal volume in clinically normal, amyloid positive adults Alzheimers Dement (Amst). 2022; 14(1):e12271. . View in PubMed
• Autosomal dominant and sporadic late onset Alzheimer’s disease share a common in vivo pathophysiology Brain. 2022 10 21; 145(10):3594-3607. . View in PubMed
• Intranasal insulin modulates cerebrospinal fluid markers of neuroinflammation in mild cognitive impairment and Alzheimer’s disease: a randomized trial Sci Rep. 2022 01 25; 12(1):1346. . View in PubMed
• The Ups and Downs of Amyloid in Alzheimer’s J Prev Alzheimers Dis. 2022; 9(1):92-95. . View in PubMed
• A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease Nat Med. 2021 Jul; 27(7):1187-1196. . View in PubMed
• The Longitudinal Early-onset Alzheimer’s Disease Study (LEADS): Framework and methodology Alzheimers Dement. 2021 12; 17(12):2043-2055. . View in PubMed
• The case for low-level BACE1 inhibition for the prevention of Alzheimer disease Nat Rev Neurol. 2021 11; 17(11):703-714. . View in PubMed
• The Amyloid-ß Pathway in Alzheimer’s Disease Mol Psychiatry. 2021 10; 26(10):5481-5503. . View in PubMed
• Using Digital Tools to Advance Alzheimer’s Drug Trials During a Pandemic: The EU/US CTAD Task Force J Prev Alzheimers Dis. 2021; 8(4):513-519. . View in PubMed
• Detection of ß-amyloid positivity in Alzheimer’s Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers Brain Commun. 2021; 3(2):fcab008. . View in PubMed
• Disparities by Race and Ethnicity Among Adults Recruited for a Preclinical Alzheimer Disease Trial JAMA Netw Open. 2021 07 01; 4(7):e2114364. . View in PubMed
• Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease: A Truncated Randomized Phase 2b/3 Clinical Trial JAMA Neurol. 2021 03 01; 78(3):293-301. . View in PubMed
• Brain amyloid burden, sleep, and 24-hour rest/activity rhythms: screening findings from the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration Studies Sleep Adv. 2021; 2(1):zpab015. . View in PubMed
• Aducanumab: Appropriate Use Recommendations J Prev Alzheimers Dis. 2021; 8(4):398-410. . View in PubMed
• Editorial: How Will Aducanumab Approval Impact AD Research? J Prev Alzheimers Dis. 2021; 8(4):391-392.. View in PubMed
• Pilot Evaluation of the Unsupervised, At-Home Cogstate Brief Battery in ADNI-2 J Alzheimers Dis. 2021; 83(2):915-925. . View in PubMed
• Feasibility study for detection of retinal amyloid in clinical trials: The Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) trial Alzheimers Dement (Amst). 2021; 13(1):e12199. . View in PubMed
• Aducanumab produced a clinically meaningful benefit in association with amyloid lowering Alzheimers Res Ther. 2021 05 10; 13(1):98. . View in PubMed
• The Impact of Amyloid Burden and APOE on Rates of Cognitive Impairment in Late Life Depression J Alzheimers Dis. 2021; 80(3):991-1002. . View in PubMed
• Late-Life Depression Is Associated With Reduced Cortical Amyloid Burden: Findings From the Alzheimer’s Disease Neuroimaging Initiative Depression Project Biol Psychiatry. 2021 04 15; 89(8):757-765. . View in PubMed
• The Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD): A Novel Clinical Trials Training Program J Prev Alzheimers Dis. 2021; 8(3):286-291. . View in PubMed
• Platform Trials to Expedite Drug Development in Alzheimer’s Disease: A Report from the EU/US CTAD Task Force J Prev Alzheimers Dis. 2021; 8(3):306-312. . View in PubMed
• Intranasal Insulin Reduces White Matter Hyperintensity Progression in Association with Improvements in Cognition and CSF Biomarker Profiles in Mild Cognitive Impairment and Alzheimer’s Disease J Prev Alzheimers Dis. 2021; 8(3):240-248. . View in PubMed
• New Hope for Alzheimer’s Disease J Prev Alzheimers Dis. 2021; 8(3):238-239. . View in PubMed
• Item-Level Investigation of Participant and Study Partner Report on the Cognitive Function Index from the A4 Study Screening Data J Prev Alzheimers Dis. 2021; 8(3):257-262. . View in PubMed
• Predicting amyloid risk by machine learning algorithms based on the A4 screen data: Application to the Japanese Trial-Ready Cohort study Alzheimers Dement (N Y). 2021; 7(1):e12135. . View in PubMed
• The Computerized Cognitive Composite (C3) in an Alzheimer’s Disease Secondary Prevention Trial J Prev Alzheimers Dis. 2021; 8(1):59-67. . View in PubMed
• Cognitive outcomes in trials of two BACE inhibitors in Alzheimer’s disease Alzheimers Dement. 2020 11; 16(11):1483-1492. . View in PubMed
• The search for Alzheimer disease therapeutics – same targets, better trials? Nat Rev Neurol. 2020 11; 16(11):597-598.. View in PubMed
• Evidence-based prevention of Alzheimer’s disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials J Neurol Neurosurg Psychiatry. 2020 11; 91(11):1201-1209. . View in PubMed
• Initiation of symptomatic medication in Alzheimer’s disease clinical trials: Hypothetical versus treatment policy approach Alzheimers Dement. 2020 05; 16(5):797-803. . View in PubMed
• The Trial-Ready Cohort for Preclinical and Prodromal Alzheimer’s Disease (TRC-PAD): Experience from the First 3 Years J Prev Alzheimers Dis. 2020; 7(4):234-241. . View in PubMed
• Instrumental activities of daily living, amyloid, and cognition in cognitively normal older adults screening for the A4 Study Alzheimers Dement (Amst). 2020; 12(1):e12118. . View in PubMed
• Early Stages of Alzheimer’s Disease: Evolving the Care Team for Optimal Patient Management Front Neurol. 2020; 11:592302. . View in PubMed
• Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals JAMA Neurol. 2020 06 01; 77(6):735-745. . View in PubMed
• Association Between Common Variants in RBFOX1, an RNA-Binding Protein, and Brain Amyloidosis in Early and Preclinical Alzheimer Disease JAMA Neurol. 2020 10 01; 77(10):1288-1298. . View in PubMed
• Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment JAMA Neurol. 2020 12 01; 77(12):1504-1513. . View in PubMed
• Data-Driven Participant Recruitment: Findings from the Alzheimer’s Disease Neuroimaging Initiative 3 J Prev Alzheimers Dis. 2020; 7(2):122-127. . View in PubMed
• The Future of Anti-Amyloid Trials J Prev Alzheimers Dis. 2020; 7(3):146-151. . View in PubMed
• Non-Amyloid Approaches to Disease Modification for Alzheimer’s Disease: An EU/US CTAD Task Force Report J Prev Alzheimers Dis. 2020; 7(3):152-157. . View in PubMed
• Neuroanatomical spread of amyloid ß and tau in Alzheimer’s disease: implications for primary prevention Brain Commun. 2020; 2(1):fcaa007. . View in PubMed
• TRC-PAD: Accelerating Recruitment of AD Clinical Trials through Innovative Information Technology J Prev Alzheimers Dis. 2020; 7(4):226-233. . View in PubMed
• Recruitment into the Alzheimer Prevention Trials (APT) Webstudy for a Trial-Ready Cohort for Preclinical and Prodromal Alzheimer’s Disease (TRC-PAD) J Prev Alzheimers Dis. 2020; 7(4):219-225. . View in PubMed
• Predicting Amyloid Burden to Accelerate Recruitment of Secondary Prevention Clinical Trials J Prev Alzheimers Dis. 2020; 7(4):213-218. . View in PubMed
• Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia: A Randomized Clinical Trial JAMA Neurol. 2020 09 01; 77(9):1099-1109. . View in PubMed
• Authors response to D Umbricht, letter to the editor referring Futility Analyses in Alzheimer’s Disease (AD) Clinical Trials: A Risky BusinessThe Journal of Prevention of Alzheimer’s Disease, 2020. J Prev Alzheimers Dis. 2020; 7(4):300. . View in PubMed
• Viewpoint: Futility Analyses in Alzheimer’s Disease (AD) Clinical Trials: A Risky Business J Prev Alzheimers Dis. 2020; 7(3):195-196. . View in PubMed
• BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer’s disease brain Brain. 2020 12 01; 143(12):3816-3826. . View in PubMed
• The Trial-Ready Cohort for Preclinical/Prodromal Alzheimer’s Disease (TRC-PAD) Project: An Overview J Prev Alzheimers Dis. 2020; 7(4):208-212. . View in PubMed
• Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease: A Randomized Clinical Trial JAMA Neurol. 2019 Oct 01; 76(10):1219-1229. . View in PubMed
• Predicting the course of Alzheimer’s progression Brain Inform. 2019 Jun 28; 6(1):6. . View in PubMed
• Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease N Engl J Med. 2019 Apr 11; 380(15):1408-1420. . View in PubMed
• Associations among amyloid status, age, and longitudinal regional brain atrophy in cognitively unimpaired older adults Neurobiol Aging. 2019 10; 82:110-119. . View in PubMed
• Frequency and longitudinal clinical outcomes of Alzheimer’s AT(N) biomarker profiles: A longitudinal study Alzheimers Dement. 2019 09; 15(9):1208-1217. . View in PubMed
• A randomized clinical trial to evaluate home-based assessment of people over 75 years old Alzheimers Dement. 2019 05; 15(5):615-624. . View in PubMed
• Alzheimer’s Disease Clinical Trials: Moving Toward Successful Prevention CNS Drugs. 2019 02; 33(2):99-106. . View in PubMed
• Understanding disease progression and improving Alzheimer’s disease clinical trials: Recent highlights from the Alzheimer’s Disease Neuroimaging Initiative Alzheimers Dement. 2019 01; 15(1):106-152. . View in PubMed
• Plasma Biomarkers of AD Emerging as Essential Tools for Drug Development: An EU/US CTAD Task Force Report J Prev Alzheimers Dis. 2019; 6(3):169-173. . View in PubMed
• Preliminary Results of a Trial of Atabecestat in Preclinical Alzheimer’s Disease N Engl J Med. 2019 04 11; 380(15):1483-1485. . View in PubMed
• The relative efficiency of time-to-progression and continuous measures of cognition in presymptomatic Alzheimer’s disease Alzheimers Dement (N Y). 2019; 5:308-318. . View in PubMed
• Unsuccessful trials of therapies for Alzheimer’s disease Lancet. 2019 01 05; 393(10166):29. . View in PubMed
• Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease Alzheimers Res Ther. 2019 08 07; 11(1):68. . View in PubMed
• Randomized, Placebo Controlled Trial of NPT088, A Phage-Derived, Amyloid-Targeted Treatment for Alzheimer’s Disease J Prev Alzheimers Dis. 2019; 6(4):228-231. . View in PubMed
• Automated and manual hippocampal segmentation techniques: Comparison of results, reproducibility and clinical applicability Neuroimage Clin. 2019; 21:101574. . View in PubMed
• Anti-Tau Trials for Alzheimer’s Disease: A Report from the EU/US/CTAD Task Force J Prev Alzheimers Dis. 2019; 6(3):157-163. . View in PubMed
• Advancing Alzheimer’s Disease Treatment: Lessons from CTAD 2018 J Prev Alzheimers Dis. 2019; 6(3):198-203. . View in PubMed
• Combination Therapy for Alzheimer’s Disease: Perspectives of the EU/US CTAD Task Force J Prev Alzheimers Dis. 2019; 6(3):164-168. . View in PubMed
• What Next in AD Drug Development? J Prev Alzheimers Dis. 2019; 6(3):150.. View in PubMed
• Participant satisfaction with dementia prevention research: Results from Home-Based Assessment trial Alzheimers Dement. 2018 11; 14(11):1397-1405. . View in PubMed
• Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial PLoS Med. 2018 09; 15(9):e1002660. . View in PubMed
• Japanese and North American Alzheimer’s Disease Neuroimaging Initiative studies: Harmonization for international trials Alzheimers Dement. 2018 08; 14(8):1077-1087. . View in PubMed
• Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease N Engl J Med. 2018 05 03; 378(18):1691-1703. . View in PubMed
• Defining the Optimal Target Population for Trials of Polyunsaturated Fatty Acid Supplementation Using the Erythrocyte Omega-3 Index: A Step Towards Personalized Prevention of Cognitive Decline? J Nutr Health Aging. 2018; 22(8):982-998.. View in PubMed
• Biomarker and Clinical Trial Design Support for Disease-Modifying Therapies: Report of a Survey of the EU/US: Alzheimer’s Disease Task Force J Prev Alzheimers Dis. 2018; 5(2):103-109. . View in PubMed
• Analysis of the Relationship of Cognitive Impairment and Functional Impairment in Mild Alzheimer’s Disease in EXPEDITION 3 J Prev Alzheimers Dis. 2018; 5(3):184-187. . View in PubMed
• Adeno-Associated Viral Vector (Serotype 2)-Nerve Growth Factor for Patients With Alzheimer Disease: A Randomized Clinical Trial JAMA Neurol. 2018 07 01; 75(7):834-841. . View in PubMed
• Author response: A phase 3 trial of IV immunoglobulin for Alzheimer disease Neurology. 2018 01 16; 90(3):145. . View in PubMed
• What We Learn from the CTAD (Clinical Trials Alzheimer’s Disease) 2018 J Prev Alzheimers Dis. 2018; 5(4):214-215. . View in PubMed
• Identifying Better Outcome Measures to Improve Treatment of Agitation in Dementia: A Report from the EU/US/CTAD Task Force J Prev Alzheimers Dis. 2018; 5(2):98-102. . View in PubMed
• Delayed-Start Analyses in the Phase 3 Solanezumab EXPEDITION3 Study in Mild Alzheimer’s Disease J Prev Alzheimers Dis. 2018; 5(1):8-14. . View in PubMed
• Estimating the Evolution of Disease in the Parkinson’s Progression Markers Initiative Neurodegener Dis. 2018; 18(4):173-190. . View in PubMed
• J Prev Alzheimers Dis. 2018; 5(3):171-174. . View in PubMed
• Bayesian latent time joint mixed-effects model of progression in the Alzheimer’s Disease Neuroimaging Initiative Alzheimers Dement (Amst). 2018; 10:657-668. . View in PubMed
• A simulation study comparing slope model with mixed-model repeated measure to assess cognitive data in clinical trials of Alzheimer’s disease Alzheimers Dement (N Y). 2018; 4:46-53. . View in PubMed
• Targeted neurogenesis pathway-based gene analysis identifies ADORA2A associated with hippocampal volume in mild cognitive impairment and Alzheimer’s disease Neurobiol Aging. 2017 Dec; 60:92-103. . View in PubMed
• Early and late change on the preclinical Alzheimer’s cognitive composite in clinically normal older individuals with elevated amyloid ß Alzheimers Dement. 2017 Sep; 13(9):1004-1012. . View in PubMed
• On the path to 2025: understanding the Alzheimer’s disease continuum Alzheimers Res Ther. 2017 Aug 09; 9(1):60. . View in PubMed
• A phase 3 trial of IV immunoglobulin for Alzheimer disease Neurology. 2017 May 02; 88(18):1768-1775. . View in PubMed
• Randomized controlled trials in mild cognitive impairment: Sources of variability Neurology. 2017 May 02; 88(18):1751-1758. . View in PubMed
• Association between tau deposition and antecedent amyloid-ß accumulation rates in normal and early symptomatic individuals Brain. 2017 May 01; 140(5):1499-1512. . View in PubMed
• The Alzheimer’s Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement Alzheimers Dement. 2017 May; 13(5):561-571. . View in PubMed
• Recent publications from the Alzheimer’s Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials Alzheimers Dement. 2017 Apr; 13(4):e1-e85. . View in PubMed
• Effects of traumatic brain injury and posttraumatic stress disorder on development of Alzheimer’s disease in Vietnam Veterans using the Alzheimer’s Disease Neuroimaging Initiative: Preliminary Report Alzheimers Dement (N Y). 2017 06; 3(2):177-188. . View in PubMed
• Editorial: Collaborative Efforts to Prevent Alzheimer’s Disease J Nutr Health Aging. 2017; 21(10):1072-1074. . View in PubMed
• Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease J Neuroinflammation. 2017 01 03; 14(1):1. . View in PubMed
• EU/US/CTAD Task Force: Lessons Learned from Recent and Current Alzheimer’s Prevention Trials J Prev Alzheimers Dis. 2017; 4(2):116-124. . View in PubMed
• Elevated Brain Amyloid in Cognitively Normal Individuals-Reply JAMA. 2017 10 10; 318(14):1393-1394. . View in PubMed
• Cross-validation of optimized composites for preclinical Alzheimer’s disease Alzheimers Dement (N Y). 2017 Jan; 3(1):123-129. . View in PubMed
• Deleterious Effect of Butyrylcholinesterase K-Variant in Donepezil Treatment of Mild Cognitive Impairment J Alzheimers Dis. 2017; 56(1):229-237. . View in PubMed
• Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimer’s disease BMC Med Genomics. 2017 05 24; 10(Suppl 1):29. . View in PubMed
• Continuing Progress in Alzheimer’s Disease Trials: Cause for Optimism J Prev Alzheimers Dis. 2017; 4(4):211-212. . View in PubMed
• The Utility of the Cognitive Function Instrument (CFI) to Detect Cognitive Decline in Non-Demented Older Adults J Alzheimers Dis. 2017; 60(2):427-437. . View in PubMed
• Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons JAMA. 2017 06 13; 317(22):2305-2316. . View in PubMed
• Statistical properties of continuous composite scales and implications for drug development J Biopharm Stat. 2017; 27(6):1104-1114. . View in PubMed
• Re-Engineering Alzheimer Clinical Trials: Global Alzheimer’s Platform Network J Prev Alzheimers Dis. 2016 Jun; 3(2):114-120. . View in PubMed
• Demonstration of safety of intravenous immunoglobulin in geriatric patients in a long-term, placebo-controlled study of Alzheimer’s disease Alzheimers Dement (N Y). 2016 Jun; 2(2):131-139. . View in PubMed
• Vitamin E in aging persons with Down syndrome: A randomized, placebo-controlled clinical trial Neurology. 2016 May 31; 86(22):2071-6. . View in PubMed
• The Feasibility of At-Home iPad Cognitive Testing For Use in Clinical Trials J Prev Alzheimers Dis. 2016 Mar; 3(1):8-12. . View in PubMed
• Preclinical Alzheimer’s disease: Definition, natural history, and diagnostic criteria Alzheimers Dement. 2016 Mar; 12(3):292-323. . View in PubMed
• Chronic Depressive Symptomatology in Mild Cognitive Impairment Is Associated with Frontal Atrophy Rate which Hastens Conversion to Alzheimer Dementia Am J Geriatr Psychiatry. 2016 Feb; 24(2):126-35. . View in PubMed
• Cognitive and functional changes associated with Aß pathology and the progression to mild cognitive impairment Neurobiol Aging. 2016 12; 48:172-181. . View in PubMed
• Collaboration for Alzheimer’s Prevention: Principles to guide data and sample sharing in preclinical Alzheimer’s disease trials Alzheimers Dement. 2016 05; 12(5):631-2. . View in PubMed
• Longitudinal decline in mild-to-moderate Alzheimer’s disease: Analyses of placebo data from clinical trials Alzheimers Dement. 2016 05; 12(5):598-603. . View in PubMed
• Drug development in Alzheimer’s disease: the path to 2025 Alzheimers Res Ther. 2016 09 20; 8:39. . View in PubMed
• Accelerating rates of cognitive decline and imaging markers associated with ß-amyloid pathology Neurology. 2016 05 17; 86(20):1887-96. . View in PubMed
• CAP–advancing the evaluation of preclinical Alzheimer disease treatments Nat Rev Neurol. 2016 Jan; 12(1):56-61. . View in PubMed
• JPAD Is Moving Fast J Prev Alzheimers Dis. 2016; 3(1):3-4. . View in PubMed
• Correlation between Cognition and Function across the Spectrum of Alzheimer’s Disease J Prev Alzheimers Dis. 2016; 3(3):138-144. . View in PubMed
• Integration of bioinformatics and imaging informatics for identifying rare PSEN1 variants in Alzheimer’s disease BMC Med Genomics. 2016 08 12; 9 Suppl 1:30. . View in PubMed
• Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults JAMA Neurol. 2016 06 01; 73(6):721-32. . View in PubMed
• Global Alzheimer’s Platform Trial Ready Cohorts for the Prevention of Alzheimer’s Dementia J Prev Alzheimers Dis. 2016; 3(4):185-187. . View in PubMed
• Registries and Cohorts to Accelerate Early Phase Alzheimer’s TrialsA Report from the E. U. /U. S. Clinical Trials in Alzheimer’s Disease Task Force. J Prev Alzheimers Dis. 2016; 3(2):68-74. . View in PubMed
• The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer’s disease Alzheimers Res Ther. 2016 06 30; 8:25. . View in PubMed
• A Combined Measure of Cognition and Function for Clinical Trials: The Integrated Alzheimer’s Disease Rating Scale (iADRS) J Prev Alzheimers Dis. 2015 Dec 01; 2(4):227-241. . View in PubMed
• APOE effect on Alzheimer’s disease biomarkers in older adults with significant memory concern Alzheimers Dement. 2015 Dec; 11(12):1417-1429. . View in PubMed
• A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease Neurology. 2015 Oct 20; 85(16):1383-91. . View in PubMed
• The transitional association between ß-amyloid pathology and regional brain atrophy Alzheimers Dement. 2015 Oct; 11(10):1171-9. . View in PubMed
• GWAS of longitudinal amyloid accumulation on 18F-florbetapir PET in Alzheimer’s disease implicates microglial activation gene IL1RAP Brain. 2015 Oct; 138(Pt 10):3076-88. . View in PubMed
• FASTKD2 is associated with memory and hippocampal structure in older adults Mol Psychiatry. 2015 Oct; 20(10):1197-204. . View in PubMed
• Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline J Alzheimers Dis. 2015 Sep 24; 48 Suppl 1:S171-91. . View in PubMed
• Delayed-start analysis: Mild Alzheimer’s disease patients in solanezumab trials, 35 years. Alzheimers Dement (N Y). 2015 Sep; 1(2):111-121. . View in PubMed
• Prevention of sporadic Alzheimer’s disease: lessons learned from clinical trials and future directions Lancet Neurol. 2015 Sep; 14(9):926-944. . View in PubMed
• Self-rated and informant-rated everyday function in comparison to objective markers of Alzheimer’s disease Alzheimers Dement. 2015 Sep; 11(9):1080-9. . View in PubMed
• Longitudinal plasma amyloid beta in Alzheimer’s disease clinical trials Alzheimers Dement. 2015 Sep; 11(9):1069-79. . View in PubMed
• Impact of the Alzheimer’s Disease Neuroimaging Initiative, 2004 to 2014 Alzheimers Dement. 2015 Jul; 11(7):865-84. . View in PubMed
• The Alzheimer’s Disease Neuroimaging Initiative phase 2: Increasing the length, breadth, and depth of our understanding Alzheimers Dement. 2015 Jul; 11(7):823-31. . View in PubMed
• The Alzheimer’s Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans Alzheimers Dement. 2015 Jul; 11(7):772-91. . View in PubMed
• Alzheimer’s Disease Neuroimaging Initiative 2 Clinical Core: Progress and plans Alzheimers Dement. 2015 Jul; 11(7):734-9. . View in PubMed
• HMGCR is a genetic modifier for risk, age of onset and MCI conversion to Alzheimer’s disease in a three cohorts study Mol Psychiatry. 2015 Jul; 20(7):867-73. . View in PubMed
• Endpoints for Pre-Dementia AD Trials: A Report from the EU/US/CTAD Task Force J Prev Alzheimers Dis. 2015 Jun; 2(2):128-135. . View in PubMed
• 2014 Update of the Alzheimer’s Disease Neuroimaging Initiative: A review of papers published since its inception Alzheimers Dement. 2015 Jun; 11(6):e1-120. . View in PubMed
• Biomarkers and cognitive endpoints to optimize trials in Alzheimer’s disease Ann Clin Transl Neurol. 2015 May; 2(5):534-47. . View in PubMed
• Predicting Reduction of Cerebrospinal Fluid ß-Amyloid 42 in Cognitively Healthy Controls JAMA Neurol. 2015 May; 72(5):554-60. . View in PubMed
• Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer’s Disease Cooperative Study Cognitive Function Instrument JAMA Neurol. 2015 Apr; 72(4):446-54. . View in PubMed
• Advances in Alzheimer’s disease drug development BMC Med. 2015 Mar 25; 13:62. . View in PubMed
• Brain structure and function as mediators of the effects of amyloid on memory Neurology. 2015 Mar 17; 84(11):1136-44. . View in PubMed
• Protective variant for hippocampal atrophy identified by whole exome sequencing Ann Neurol. 2015 Mar; 77(3):547-52. . View in PubMed
• Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer’s Disease J Alzheimers Dis. 2015; 47(1):205-14. . View in PubMed
• Alzheimers Res Ther. 2015; 7(1):36. . View in PubMed
• The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer’s disease biomarkers in down syndrome Front Behav Neurosci. 2015; 9:239. . View in PubMed
• Alzheimer’s disease progression by geographical region in a clinical trial setting Alzheimers Res Ther. 2015; 7(1):43. . View in PubMed
• Variables associated with hippocampal atrophy rate in normal aging and mild cognitive impairment Neurobiol Aging. 2015 Jan; 36(1):273-82. . View in PubMed
• Advances in the therapy of Alzheimer’s disease: targeting amyloid beta and tau and perspectives for the future Expert Rev Neurother. 2015 Jan; 15(1):83-105. . View in PubMed
• Cognitive/Clinical Endpoints for Pre-Dementia AD Trials J Prev Alzheimers Dis. 2015; 2(2):82-84. . View in PubMed
• Cognitive and functional decline and their relationship in patients with mild Alzheimer’s dementia J Alzheimers Dis. 2015; 43(3):949-55. . View in PubMed
• Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer’s disease clinical trials Alzheimers Res Ther. 2015; 7(1):39. . View in PubMed
• The Road Ahead to Cure Alzheimer’s Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations J Prev Alzheimers Dis. 2014 Dec; 1(3):181-202. . View in PubMed
• Estimating long-term multivariate progression from short-term data Alzheimers Dement. 2014 Oct; 10(5 Suppl):S400-10. . View in PubMed
• 2014 Report on the Milestones for the US National Plan to Address Alzheimer’s Disease Alzheimers Dement. 2014 Oct; 10(5 Suppl):S430-52. . View in PubMed
• The Alzheimer’s disease cooperative study prevention instrument project: longitudinal outcome of behavioral measures as predictors of cognitive decline Dement Geriatr Cogn Dis Extra. 2014 Sep-Dec; 4(3):509-16. . View in PubMed
• The preclinical Alzheimer cognitive composite: measuring amyloid-related decline JAMA Neurol. 2014 Aug; 71(8):961-70. . View in PubMed
• Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis Neurology. 2014 Jul 15; 83(3):253-60. . View in PubMed
• Effects of traumatic brain injury and posttraumatic stress disorder on Alzheimer’s disease in veterans, using the Alzheimer’s Disease Neuroimaging Initiative Alzheimers Dement. 2014 Jun; 10(3 Suppl):S226-35. . View in PubMed
• Alzheimer’s Disease Cooperative Study Prevention Instrument Project assessing resource use and volunteer and paid work in healthy elders: a longitudinal study J Am Geriatr Soc. 2014 May; 62(5):985-8. . View in PubMed
• Clinical trial of an inhibitor of RAGE-Aß interactions in Alzheimer disease Neurology. 2014 Apr 29; 82(17):1536-42. . View in PubMed
• Serum brain-derived neurotrophic factor and the risk for dementia JAMA. 2014 Apr 23-30; 311(16):1684-5. . View in PubMed
• Perspective on future role of biological markers in clinical therapy trials of Alzheimer’s disease: a long-range point of view beyond 2020 Biochem Pharmacol. 2014 Apr 15; 88(4):426-49. . View in PubMed
• The A4 study: stopping AD before symptoms begin? Sci Transl Med. 2014 Mar 19; 6(228):228fs13.. View in PubMed
• APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study Mol Psychiatry. 2014 Mar; 19(3):351-7. . View in PubMed
• Neuropsychiatric symptoms and regional neocortical atrophy in mild cognitive impairment and Alzheimer’s disease Am J Alzheimers Dis Other Demen. 2014 Mar; 29(2):159-65. . View in PubMed
• Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease N Engl J Med. 2014 Jan 23; 370(4):311-21. . View in PubMed
• Effect of TTP488 in patients with mild to moderate Alzheimer’s disease BMC Neurol. 2014 Jan 15; 14:12. . View in PubMed
• Phase 3 trials of solanezumab and bapineuzumab for Alzheimer’s disease N Engl J Med. 2014 04 10; 370(15):1460. . View in PubMed
• Journal of Prevention of Alzheimer’s Disease (JPAD): Building a “Fleet” Against Alzheimer’s Disease J Prev Alzheimers Dis. 2014; 1(1):2-3. . View in PubMed
• Association of plasma and cortical amyloid beta is modulated by APOE e4 status Alzheimers Dement. 2014 Jan; 10(1):e9-e18. . View in PubMed
• EU/U. S. CTAD Task Force on Alzheimer’s Trial Populations. J Prev Alzheimers Dis. 2014; 1(2):110-116. . View in PubMed
• Regional variability of imaging biomarkers in autosomal dominant Alzheimer’s disease Proc Natl Acad Sci U S A. 2013 Nov 19; 110(47):E4502-9. . View in PubMed
• Detecting When “Quality of Life” Has Been “Enhanced”: Estimating Change in Quality of Life Ratings Open J Philos. 2013 Nov 01; 3(4A):24-31. . View in PubMed
• Focal hemosiderin deposits and ß-amyloid load in the ADNI cohort Alzheimers Dement. 2013 Oct; 9(5 Suppl):S116-23. . View in PubMed
• Developing dementia prevention trials: baseline report of the Home-Based Assessment study Alzheimer Dis Assoc Disord. 2013 Oct-Dec; 27(4):356-62. . View in PubMed
• Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial Rev Neurol (Paris). 2013 Oct; 169(10):737-43. . View in PubMed
• The Alzheimer’s Disease Neuroimaging Initiative: a review of papers published since its inception Alzheimers Dement. 2013 Sep; 9(5):e111-94. . View in PubMed
• The effect of subsyndromal symptoms of depression and white matter lesions on disability for individuals with mild cognitive impairment Am J Geriatr Psychiatry. 2013 Sep; 21(9):906-14. . View in PubMed
• Mild cognitive impairment due to Alzheimer disease in the community Ann Neurol. 2013 Aug; 74(2):199-208. . View in PubMed
• A phase 3 trial of semagacestat for treatment of Alzheimer’s disease N Engl J Med. 2013 Jul 25; 369(4):341-50. . View in PubMed
• Age and apolipoprotein E genotype influence rate of cognitive decline in nondemented elderly Neuropsychology. 2013 Jul; 27(4):391-401. . View in PubMed
• Whole-exome sequencing and imaging genetics identify functional variants for rate of change in hippocampal volume in mild cognitive impairment Mol Psychiatry. 2013 Jul; 18(7):781-7. . View in PubMed
• Designing drug trials for Alzheimer’s disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force Alzheimers Dement. 2013 Jul; 9(4):438-44. . View in PubMed
• Identification of functional variants from whole-exome sequencing, combined with neuroimaging genetics Mol Psychiatry. 2013 Jul; 18(7):739. . View in PubMed
• Ventricular enlargement and its clinical correlates in the imaging cohort from the ADCS MCI donepezil/vitamin E study Alzheimer Dis Assoc Disord. 2013 Apr-Jun; 27(2):174-81. . View in PubMed
• Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer’s disease Nat Rev Drug Discov. 2013 Apr; 12(4):324. . View in PubMed
• Health-related resource use and costs in elderly adults with and without mild cognitive impairment J Am Geriatr Soc. 2013 Mar; 61(3):396-402. . View in PubMed
• Apolipoprotein E epsilon4 does not modulate amyloid-ß-associated neurodegeneration in preclinical Alzheimer disease AJNR Am J Neuroradiol. 2013 Mar; 34(3):505-10. . View in PubMed
• Antioxidants for Alzheimer disease-reply JAMA Neurol. 2013 Feb; 70(2):270-1. . View in PubMed
• Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers Lancet Neurol. 2013 Feb; 12(2):207-16. . View in PubMed
• Effect of study partner on the conduct of Alzheimer disease clinical trials Neurology. 2013 Jan 15; 80(3):282-8. . View in PubMed
• Semagacestat for treatment of Alzheimer’s disease N Engl J Med. 2013 10 24; 369(17):1661. . View in PubMed
• Influence of genetic variation on plasma protein levels in older adults using a multi-analyte panel PLoS One. 2013; 8(7):e70269. . View in PubMed
• Early indications of future cognitive decline: stable versus declining controls PLoS One. 2013; 8(9):e74062. . View in PubMed
• Passive immunotherapy for Alzheimer’s disease: what have we learned, and where are we headed? J Nutr Health Aging. 2013 Jan; 17(1):49-50.. View in PubMed
• The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI) Front Aging Neurosci. 2013; 5:11. . View in PubMed
• Genome-wide pathway analysis of memory impairment in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort implicates gene candidates, canonical pathways, and networks Brain Imaging Behav. 2012 Dec; 6(4):634-48. . View in PubMed
• Amyloid deposition, hypometabolism, and longitudinal cognitive decline Ann Neurol. 2012 Oct; 72(4):578-86. . View in PubMed
• Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network Clin Investig (Lond). 2012 Oct 01; 2(10):975-984. . View in PubMed
• CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects Cereb Cortex. 2012 Sep; 22(9):1993-2004. . View in PubMed
• Clinical and biomarker changes in dominantly inherited Alzheimer’s disease N Engl J Med. 2012 Aug 30; 367(9):795-804. . View in PubMed
• Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials Arch Neurol. 2012 Jul; 69(7):901-5. . View in PubMed
• Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease Alzheimers Dement. 2012 Jul; 8(4):261-71. . View in PubMed
• Shapes of the trajectories of 5 major biomarkers of Alzheimer disease Arch Neurol. 2012 Jul; 69(7):856-67. . View in PubMed
• Longitudinal plasma amyloid beta as a biomarker of Alzheimer’s disease J Neural Transm (Vienna). 2012 Jul; 119(7):843-50. . View in PubMed
• Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures Arch Neurol. 2012 Jul; 69(7):836-41. . View in PubMed
• Considerations in the design of clinical trials for cognitive aging J Gerontol A Biol Sci Med Sci. 2012 Jun; 67(7):766-72. . View in PubMed
• Amyloid-ß–associated clinical decline occurs only in the presence of elevated P-tau Arch Neurol. 2012 Jun; 69(6):709-13. . View in PubMed
• Nonlinear time course of brain volume loss in cognitively normal and impaired elders Neurobiol Aging. 2012 May; 33(5):845-55. . View in PubMed
• Mixed model of repeated measures versus slope models in Alzheimer’s disease clinical trials J Nutr Health Aging. 2012 Apr; 16(4):360-4. . View in PubMed
• Longitudinal stability of subsyndromal symptoms of depression in individuals with mild cognitive impairment: relationship to conversion to dementia after 3 years Int J Geriatr Psychiatry. 2012 Apr; 27(4):355-63. . View in PubMed
• Alzheimer’s disease therapeutic trials: EU/US Task Force report on recruitment, retention, and methodology J Nutr Health Aging. 2012 Apr; 16(4):339-45. . View in PubMed
• Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans Proc Natl Acad Sci U S A. 2012 Mar 06; 109(10):3985-90. . View in PubMed
• Incidence of new-onset seizures in mild to moderate Alzheimer disease Arch Neurol. 2012 Mar; 69(3):368-72. . View in PubMed
• Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease Cold Spring Harb Perspect Med. 2012 Mar; 2(3):a006395. . View in PubMed
• The Alzheimer’s Disease Neuroimaging Initiative: a review of papers published since its inception Alzheimers Dement. 2012 Feb; 8(1 Suppl):S1-68. . View in PubMed
• Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial Neurology. 2012 Jan 10; 78(2):91-101. . View in PubMed
• Down’s syndrome and Alzheimer’s disease: towards secondary prevention Nat Rev Drug Discov. 2012 09; 11(9):655-6. . View in PubMed
• Using the Guttman scale to define and estimate measurement error in items over time: the case of cognitive decline and the meaning of “points lost” PLoS One. 2012; 7(2):e30019. . View in PubMed
• Biomarkers for Alzheimer’s disease therapeutic trials Prog Neurobiol. 2011 Dec; 95(4):579-93. . View in PubMed
• Evidence for ordering of Alzheimer disease biomarkers Arch Neurol. 2011 Dec; 68(12):1526-35. . View in PubMed
• Clinical trial methodologies for disease-modifying therapeutic approaches Neurobiol Aging. 2011 Dec; 32 Suppl 1:S64-6. . View in PubMed
• Prevention trials in Alzheimer’s disease: an EU-US task force report Prog Neurobiol. 2011 Dec; 95(4):594-600. . View in PubMed
• Testing the right target and right drug at the right stage Sci Transl Med. 2011 Nov 30; 3(111):111cm33. . View in PubMed
• Genome-wide association study identifies multiple novel loci associated with disease progression in subjects with mild cognitive impairment Transl Psychiatry. 2011 Nov 15; 1:e54. . View in PubMed
• Factors affecting Aß plasma levels and their utility as biomarkers in ADNI Acta Neuropathol. 2011 Oct; 122(4):401-13. . View in PubMed
• Amyloid-ß associated volume loss occurs only in the presence of phospho-tau Ann Neurol. 2011 Oct; 70(4):657-61. . View in PubMed
• Longitudinal change of biomarkers in cognitive decline Arch Neurol. 2011 Oct; 68(10):1257-66. . View in PubMed
• Chronic divalproex sodium use and brain atrophy in Alzheimer disease Neurology. 2011 Sep 27; 77(13):1263-71. . View in PubMed
• Impact of apolipoprotein E4-cerebrospinal fluid ß-amyloid interaction on hippocampal volume loss over 1 year in mild cognitive impairment Alzheimers Dement. 2011 Sep; 7(5):514-20. . View in PubMed
• The relative efficiency of time-to-threshold and rate of change in longitudinal data Contemp Clin Trials. 2011 Sep; 32(5):685-93. . View in PubMed
• Q&A: The Alzheimer’s Disease Neuroimaging Initiative BMC Med. 2011 Sep 01; 9:101. . View in PubMed
• A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease Neurology. 2011 Aug 09; 77(6):556-63. . View in PubMed
• Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease Arch Gen Psychiatry. 2011 Aug; 68(8):853-61. . View in PubMed
• AMPA workshop on challenges faced by investigators conducting Alzheimer’s disease clinical trials Alzheimers Dement. 2011 Jul; 7(4):e109-17. . View in PubMed
• PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease Alzheimer Dis Assoc Disord. 2011 Jul-Sep; 25(3):206-12. . View in PubMed
• Cognitive reserve and Alzheimer’s disease biomarkers are independent determinants of cognition Brain. 2011 May; 134(Pt 5):1479-92. . View in PubMed
• Commentary on “Biomarkers in Alzheimer’s disease drug development” Can’t live without ’em. Alzheimers Dement. 2011 May; 7(3):e48-50. . View in PubMed
• Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease Alzheimers Dement. 2011 May; 7(3):280-92. . View in PubMed
• A phase II trial of huperzine A in mild to moderate Alzheimer disease Neurology. 2011 Apr 19; 76(16):1389-94. . View in PubMed
• Adding delayed recall to the Alzheimer Disease Assessment Scale is useful in studies of mild cognitive impairment but not Alzheimer disease Alzheimer Dis Assoc Disord. 2011 Apr-Jun; 25(2):122-7. . View in PubMed
• Developing a global strategy to prevent Alzheimer’s disease: Leon Thal Symposium 2010 Alzheimers Dement. 2011 Mar; 7(2):127-32. . View in PubMed
• Requiring an amyloid-ß1-42 biomarker for prodromal Alzheimer’s disease or mild cognitive impairment does not lead to more efficient clinical trials Alzheimers Dement. 2011 Mar; 7(2):245-6; author reply 247-9. . View in PubMed
• Transforming cerebrospinal fluid Aß42 measures into calculated Pittsburgh Compound B units of brain Aß amyloid Alzheimers Dement. 2011 Mar; 7(2):133-41. . View in PubMed
• Tramiprosate in mild-to-moderate Alzheimer’s disease – a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study) Arch Med Sci. 2011 Feb; 7(1):102-11. . View in PubMed
• Report of the task force on designing clinical trials in early (predementia) AD Neurology. 2011 Jan 18; 76(3):280-6. . View in PubMed
• A humanin derivative reduces amyloid beta accumulation and ameliorates memory deficit in triple transgenic mice PLoS One. 2011 Jan 17; 6(1):e16259. . View in PubMed
• Autosomal-dominant Alzheimer’s disease: a review and proposal for the prevention of Alzheimer’s disease Alzheimers Res Ther. 2011 Jan 06; 3(1):1. . View in PubMed
• Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort Neurology. 2011 Jan 04; 76(1):69-79. . View in PubMed
• A lead study on oxidative stress-mediated dehydroepiandrosterone formation in serum: the biochemical basis for a diagnosis of Alzheimer’s disease J Alzheimers Dis. 2011; 24 Suppl 2:5-16. . View in PubMed
• Hippocampal atrophy rates and CSF biomarkers in elderly APOE2 normal subjects Neurology. 2010 Nov 30; 75(22):1976-81. . View in PubMed
• Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial JAMA. 2010 Nov 03; 304(17):1903-11. . View in PubMed
• Dependence as a unifying construct in defining Alzheimer’s disease severity Alzheimers Dement. 2010 Nov; 6(6):482-93. . View in PubMed
• Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer’s disease Brain. 2010 Nov; 133(11):3336-48. . View in PubMed
• Influence of apolipoprotein E varepsilon4 on rates of cognitive and functional decline in mild cognitive impairment Alzheimers Dement. 2010 Sep; 6(5):412-9. . View in PubMed
• Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study Neurobiol Aging. 2010 Aug; 31(8):1340-54. . View in PubMed
• 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects Neurobiol Aging. 2010 Aug; 31(8):1284-303. . View in PubMed
• Comparing predictors of conversion and decline in mild cognitive impairment Neurology. 2010 Jul 20; 75(3):230-8. . View in PubMed
• Serial MRI and CSF biomarkers in normal aging, MCI, and AD Neurology. 2010 Jul 13; 75(2):143-51. . View in PubMed
• Neuroimaging enrichment strategy for secondary prevention trials in Alzheimer disease Alzheimer Dis Assoc Disord. 2010 Jul-Sep; 24(3):269-77. . View in PubMed
• Biological markers of amyloid beta-related mechanisms in Alzheimer’s disease Exp Neurol. 2010 Jun; 223(2):334-46. . View in PubMed
• Clinical Core of the Alzheimer’s Disease Neuroimaging Initiative: progress and plans Alzheimers Dement. 2010 May; 6(3):239-46. . View in PubMed
• Update on the biomarker core of the Alzheimer’s Disease Neuroimaging Initiative subjects Alzheimers Dement. 2010 May; 6(3):230-8. . View in PubMed
• The Alzheimer’s disease neuroimaging initiative: progress report and future plansAlzheimers Dement. 2010 May; 6(3):202-11. e7. . View in PubMed
• 3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI Hum Brain Mapp. 2010 May; 31(5):786-97. . View in PubMed
• NIA-funded Alzheimer centers are more efficient than commercial clinical recruitment sites for conducting secondary prevention trials of dementia Alzheimer Dis Assoc Disord. 2010 Apr-Jun; 24(2):159-64. . View in PubMed
• Pre-dementia Alzheimer’s trials: overview J Nutr Health Aging. 2010 Apr; 14(4):294. . View in PubMed
• Early Alzheimer’s trials: new developments J Nutr Health Aging. 2010 Apr; 14(4):293. . View in PubMed
• Therapeutics for cognitive aging Ann N Y Acad Sci. 2010 Apr; 1191 Suppl 1:E1-15. . View in PubMed
• Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease Ann Neurol. 2010 Mar; 67(3):308-16. . View in PubMed
• Developing a national strategy to prevent dementia: Leon Thal Symposium 2009 Alzheimers Dement. 2010 Mar; 6(2):89-97. . View in PubMed
• Alzheimer’s Disease Neuroimaging Initiative (ADNI): clinical characterization Neurology. 2010 Jan 19; 74(3):201-9. . View in PubMed
• Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade Lancet Neurol. 2010 Jan; 9(1):119-28. . View in PubMed
• What the CERAD Battery Can Tell Us about Executive Function as a Higher-Order Cognitive Faculty Curr Gerontol Geriatr Res. 2010; 510614. . View in PubMed
• Restoration of norepinephrine-modulated contextual memory in a mouse model of Down syndrome Sci Transl Med. 2009 Nov 18; 1(7):7ra17. . View in PubMed
• MRI substudy participation in Alzheimer disease (AD) clinical trials: baseline comparability of a substudy sample to entire study population Alzheimer Dis Assoc Disord. 2009 Oct-Dec; 23(4):333-6. . View in PubMed
• The relationship of plasma Abeta levels to dementia in aging individuals with Down syndrome Alzheimer Dis Assoc Disord. 2009 Oct-Dec; 23(4):315-8. . View in PubMed
• No cross-sectional influence of APOE epsilon4 dose on clinical tests in Alzheimer’s disease Neurobiol Aging. 2009 Aug; 30(8):1327-8. . View in PubMed
• Alzheimer’s disease therapeutic research: the path forward Alzheimers Res Ther. 2009 Jul 09; 1(1):2. . View in PubMed
• Can lithium or valproate untie tangles in Alzheimer’s disease? J Clin Psychiatry. 2009 Jun; 70(6):919-21.. View in PubMed
• Effect of tramiprosate in patients with mild-to-moderate Alzheimer’s disease: exploratory analyses of the MRI sub-group of the Alphase study J Nutr Health Aging. 2009 Jun; 13(6):550-7. . View in PubMed
• The net effect of alternative allocation ratios on recruitment time and trial cost Clin Trials. 2009 Apr; 6(2):126-32. . View in PubMed
• Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects Ann Neurol. 2009 Apr; 65(4):403-13. . View in PubMed
• Interpreting biomarker data in therapeutic trials J Nutr Health Aging. 2009 Apr; 13(4):337-8. . View in PubMed
• Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer’s disease: the ALZHEMED (Tramiprosate) experience J Nutr Health Aging. 2009 Apr; 13(4):370-2. . View in PubMed
• Commentary on “a roadmap for the prevention of dementia IILeon Thal Symposium 2008. ” Facilitating Alzheimer’s disease drug development in the United States. Alzheimers Dement. 2009 Mar; 5(2):125-7. . View in PubMed
• A roadmap for the prevention of dementia II: Leon Thal Symposium 2008 Alzheimers Dement. 2009 Mar; 5(2):85-92. . View in PubMed
• Recent developments in Alzheimer’s disease therapeutics BMC Med. 2009 Feb 19; 7:7. . View in PubMed
• Levels of soluble and insoluble tau reflect overall status of tau phosphorylation in vivo Neurosci Lett. 2009 Jan 23; 450(1):51-5. . View in PubMed
• Plasma urate and progression of mild cognitive impairment Neurodegener Dis. 2009; 6(1-2):23-8. . View in PubMed
• Agreement in cognitive and clinical assessments in Alzheimer’s disease Dement Geriatr Cogn Disord. 2009; 27(4):344-52. . View in PubMed
• Methodological issues in primary prevention trials for neurodegenerative dementia J Alzheimers Dis. 2009; 16(2):235-70. . View in PubMed
• Applications of neuroimaging to disease-modification trials in Alzheimer’s disease Behav Neurol. 2009; 21(1):129-36. . View in PubMed
• High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial JAMA. 2008 Oct 15; 300(15):1774-83. . View in PubMed
• Amyloid-based therapeutics: findings translated into novel treatments CNS Spectr. 2008 Oct; 13(10 Suppl 16):36-8. . View in PubMed
• Protection of red blood cell acetylcholinesterase by oral huperzine A against ex vivo soman exposure: next generation prophylaxis and sequestering of acetylcholinesterase over butyrylcholinesterase Chem Biol Interact. 2008 Sep 25; 175(1-3):380-6. . View in PubMed
• Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease Arch Neurol. 2008 Aug; 65(8):1031-8. . View in PubMed
• Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer’s disease: a randomised, double-blind, placebo-controlled study Lancet. 2008 Jul 19; 372(9634):207-15. . View in PubMed
• Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model Brain Res. 2008 Jun 24; 1216:92-103. . View in PubMed
• Tarenflurbil: a shot on goal Lancet Neurol. 2008 Jun; 7(6):468-9. . View in PubMed
• Treatment for MCI: is the evidence sufficient? Neurology. 2008 May 27; 70(22):2020-1.. View in PubMed
• A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium Alzheimers Dement. 2008 May; 4(3):156-63. . View in PubMed
• Beta-site amyloid precursor protein-cleaving enzyme-1 (BACE1)-mediated changes of endogenous amyloid beta in wild-type and transgenic mice in vivo Neurosci Lett. 2008 Apr 25; 435(3):186-9. . View in PubMed
• A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer’s disease J Pharmacol Exp Ther. 2008 Apr; 325(1):146-53. . View in PubMed
• Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trial Curr Alzheimer Res. 2008 Feb; 5(1):73-82. . View in PubMed
• An update on huperzine A as a treatment for Alzheimer’s disease Expert Opin Investig Drugs. 2008 Feb; 17(2):209-15. . View in PubMed
• Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment Neurology. 2008 Jan 15; 70(3):191-9. . View in PubMed
• Leon Thal and the therapeutic age of Alzheimer’s disease Alzheimers Dement. 2008 Jan; 4(1 Suppl 1):S4-6. . View in PubMed
• The inflammatory hypothesis of Alzheimer disease: dead or alive? Alzheimer Dis Assoc Disord. 2008 Jan-Mar; 22(1):4-5.. View in PubMed
• An aspirin a day for Alzheimer’s disease? Lancet Neurol. 2008 Jan; 7(1):20-1.. View in PubMed
• Deglycosylated anti-amyloid beta antibodies reduce microglial phagocytosis and cytokine production while retaining the capacity to induce amyloid beta sequestration Eur J Neurosci. 2007 Nov; 26(9):2458-68. . View in PubMed
• Commentary on “The Third Canadian Consensus Conference on the Diagnosis and Treatment of Dementia, 2006”–an appraisal. Alzheimers Dement. 2007 Oct; 3(4):446-8. . View in PubMed
• Alzhemed: a potential treatment for Alzheimer’s disease Curr Alzheimer Res. 2007 Sep; 4(4):473-8. . View in PubMed
• Antibody against C-terminal Abeta selectively elevates plasma Abeta Neuroreport. 2007 Feb 12; 18(3):293-6. . View in PubMed
• A simple method to rule out dementia with temporal orientation Alzheimers Dement. 2007 Jan; 3(1):28-32. . View in PubMed
• Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer’s disease at early pathological stage J Mol Neurosci. 2007; 31(2):165-70. . View in PubMed
• BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice J Neurochem. 2006 Dec; 99(6):1555-63. . View in PubMed
• A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease Neurology. 2006 Nov 28; 67(10):1757-63. . View in PubMed
• ADCS Prevention Instrument Project: overview and initial results Alzheimer Dis Assoc Disord. 2006 Oct-Dec; 20(4 Suppl 3):S109-23. . View in PubMed
• Independent contributions of neural and “higher-order” deficits to symptoms in Alzheimer’s disease: a latent variable modeling approach Alzheimers Dement. 2006 Oct; 2(4):303-13. . View in PubMed
• Commentary on “Challenges to demonstrating disease-modifying effects in Alzheimer’s disease clinical trials” Alzheimers Dement. 2006 Oct; 2(4):272-4. . View in PubMed
• ADCS Prevention Instrument Project: the Mail-In Cognitive Function Screening Instrument (MCFSI) Alzheimer Dis Assoc Disord. 2006 Oct-Dec; 20(4 Suppl 3):S170-8. . View in PubMed
• Development of a disease-modifying treatment for Alzheimer’s disease: Alzhemed Alzheimers Dement. 2006 Jul; 2(3):153-4. . View in PubMed
• In vivo protein transduction to the CNS Neuroscience. 2006; 139(3):1061-7. . View in PubMed
• Oral administration of pyridostigmine bromide and huperzine A protects human whole blood cholinesterases from ex vivo exposure to soman Chem Biol Interact. 2005 Dec 15; 157-158:239-46. . View in PubMed
• Can rofecoxib delay a diagnosis of Alzheimer’s disease in patients with mild cognitive impairment? Nat Clin Pract Neurol. 2005 Nov; 1(1):20-1.. View in PubMed
• One-trial 10-item free-recall performance in Taiwanese elderly and near-elderly: A potential screen for cognitive decline Am J Alzheimers Dis Other Demen. 2005 Jul-Aug; 20(4):239-47. . View in PubMed
• An Abeta sequestration approach using non-antibody Abeta binding agents Curr Alzheimer Res. 2005 Apr; 2(2):265-8. . View in PubMed
• Pharmacologic treatment options in Alzheimer’s disease: optimizing disease management J Am Acad Nurse Pract. 2005 Mar; Suppl:5-7. . View in PubMed
• The development of anti-amyloid therapy for Alzheimer’s disease : from secretase modulators to polymerisation inhibitors CNS Drugs. 2005; 19(12):989-96. . View in PubMed
• Benchmarking a test of temporal orientation with data from american and taiwanese persons with Alzheimer’s disease and american normal elderly Neuroepidemiology. 2005; 24(1-2):110-6. . View in PubMed
• NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP) CNS Drug Rev. 2005; 11(4):353-68. . View in PubMed
• Inflammatory processes and Alzheimer’s disease Expert Rev Neurother. 2004 Sep; 4(5):793-8. . View in PubMed
• Development of Abeta terminal end-specific antibodies and sensitive ELISA for Abeta variant Biochem Biophys Res Commun. 2004 Jul 02; 319(3):733-7. . View in PubMed
• Georgetown University School of Medicine Acad Med. 2004 Jul; 79(7 Suppl):S45-50. . View in PubMed
• Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials Arch Neurol. 2004 Jan; 61(1):59-66. . View in PubMed
• Anti-inflammatory therapy in Alzheimer’s disease: is hope still alive? J Neurol. 2003 Jul; 250(7):788-92.. View in PubMed
• Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial JAMA. 2003 Jun 04; 289(21):2819-26. . View in PubMed
• NSAIDs and hypertension Arch Intern Med. 2003 May 12; 163(9):1115; author reply 1115-6. . View in PubMed
• A pilot study of vitamins to lower plasma homocysteine levels in Alzheimer disease Am J Geriatr Psychiatry. 2003 Mar-Apr; 11(2):246-9. . View in PubMed
• Steroid-induced elevation of glucose in Alzheimer’s disease: relationship to gender, apolipoprotein E genotype and cognition Psychoneuroendocrinology. 2003 Jan; 28(1):113-20. . View in PubMed
• Detection of apolipoprotein E phenotype in unconcentrated cerebrospinal fluid J Clin Lab Anal. 2003; 17(1):18-21. . View in PubMed
• The potential of anti-inflammatory drugs for the treatment of Alzheimer’s disease Lancet Neurol. 2002 Sep; 1(5):279-84. . View in PubMed
• Anti-inflammatory agents in Alzheimer’s disease Curr Neurol Neurosci Rep. 2002 Sep; 2(5):405-9. . View in PubMed
• Cyclooxygenase (COX)-2 and cell cycle activity in a transgenic mouse model of Alzheimer’s disease neuropathology Neurobiol Aging. 2002 May-Jun; 23(3):327-34. . View in PubMed
• Randomized pilot study of nimesulide treatment in Alzheimer’s disease Neurology. 2002 Apr 09; 58(7):1050-4. . View in PubMed
• Evaluation of selective COX-2 inhibitors for the treatment of Alzheimer’s disease J Pain Symptom Manage. 2002 Apr; 23(4 Suppl):S35-40. . View in PubMed
• Induction of the complement component C1qB in brain of transgenic mice with neuronal overexpression of human cyclooxygenase-2 Acta Neuropathol. 2002 Feb; 103(2):157-62. . View in PubMed
• Chemistry and biology of eukaryotic iron metabolism Int J Biochem Cell Biol. 2001 Oct; 33(10):940-59. . View in PubMed
• Detection of melanin-like pigments in the dimorphic fungal pathogen Paracoccidioides brasiliensis in vitro and during infection Infect Immun. 2001 Sep; 69(9):5760-7. . View in PubMed
• Pilot tolerability studies of hydroxychloroquine and colchicine in Alzheimer disease Alzheimer Dis Assoc Disord. 2001 Apr-Jun; 15(2):96-101. . View in PubMed
• Neuronal cyclooxygenase 2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer disease Arch Neurol. 2001 Mar; 58(3):487-92. . View in PubMed
• Altered expression of a-type but not b-type synapsin isoform in the brain of patients at high risk for Alzheimer’s disease assessed by DNA microarray technique Neurosci Lett. 2001 Feb 09; 298(3):191-4. . View in PubMed
• Non-steroidal anti-inflammatory drugs protect against chondrocyte apoptotic death Clin Exp Rheumatol. 2001; 19(1 Suppl 22):S7-11. . View in PubMed
• Elevated plasma neopterin levels in Alzheimer disease Alzheimer Dis Assoc Disord. 2000 Oct-Dec; 14(4):228-30. . View in PubMed
• Cytokine gene expression as a function of the clinical progression of Alzheimer disease dementia Arch Neurol. 2000 Aug; 57(8):1153-60. . View in PubMed
• Elevated CSF prostaglandin E2 levels in patients with probable AD Neurology. 2000 Jul 25; 55(2):323. . View in PubMed
• Anti-inflammatory therapy for Alzheimer’s disease Neurobiol Aging. 2000 May-Jun; 21(3):447-8; discussion 451-3. . View in PubMed
• A randomized controlled trial of prednisone in Alzheimer’s diseaseAlzheimer’s Disease Cooperative Study. Neurology. 2000 Feb 08; 54(3):588-93. . View in PubMed
• Anti-inflammatory therapy for Alzheimer’s disease: implications of the prednisone trial Acta Neurol Scand Suppl. 2000; 176:85-9. . View in PubMed
• Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease Arch Neurol. 2000 Jan; 57(1):100-5. . View in PubMed
• Increased levels of tau-like protein in patients with Down syndrome Neurosci Lett. 1999 Nov 19; 275(3):159-62. . View in PubMed
• Potentiation of excitotoxicity in transgenic mice overexpressing neuronal cyclooxygenase-2 Am J Pathol. 1999 Sep; 155(3):995-1004. . View in PubMed
• Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer’s disease J Neurosci Res. 1999 Aug 01; 57(3):295-303. . View in PubMed
• Complement-derived anaphylatoxin C5a protects against glutamate-mediated neurotoxicity J Cell Biochem. 1999 Jun 01; 73(3):303-11. . View in PubMed
• Iron metabolism Curr Opin Chem Biol. 1999 Apr; 3(2):200-6. . View in PubMed
• HLA-DR4 influences glial activity in Alzheimer’s disease hippocampus J Neurol Sci. 1998 Nov 26; 161(1):66-9. . View in PubMed
• Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer’s disease brain Neuroscience. 1998 Nov; 87(2):319-24. . View in PubMed
• Induction of cyclooxygenase (COX)-2 but not COX-1 gene expression in apoptotic cell death J Neuroimmunol. 1998 Aug 14; 89(1-2):142-9. . View in PubMed
• Association of elevated alpha 1-antichymotrypsin with cognitive impairment in a prospective study of the very old Am J Psychiatry. 1998 May; 155(5):698-700. . View in PubMed
• Glucocorticoids in Alzheimer’s diseaseThe story so far. Drugs Aging. 1998 Jan; 12(1):1-6. . View in PubMed
• Transferrin, the transferrin receptor, and the uptake of iron by cells Met Ions Biol Syst. 1998; 35:585-631. . View in PubMed
• A kinetically active site in the C-lobe of human transferrin Biochemistry. 1997 Sep 09; 36(36):11036-43. . View in PubMed
• The search for disease-modifying treatment for Alzheimer’s disease Neurology. 1997 May; 48(5 Suppl 6):S35-41. . View in PubMed
• Maturational regulation and regional induction of cyclooxygenase-2 in rat brain: implications for Alzheimer’s disease Exp Neurol. 1997 Apr; 144(2):339-49. . View in PubMed
• Selegiline in the treatment of behavioural disturbance in Alzheimer’s disease Int J Geriatr Psychiatry. 1997 Mar; 12(3):319-22. . View in PubMed
• Inflammation and Alzheimer’s disease: mechanisms and therapeutic strategies Gerontology. 1997; 43(1-2):143-9. . View in PubMed
• A pilot study of prednisone in Alzheimer’s disease Dementia. 1996 Jul-Aug; 7(4):201-6. . View in PubMed
• Melanin, melanin “ghosts,” and melanin composition in Cryptococcus neoformans Infect Immun. 1996 Jul; 64(7):2420-4. . View in PubMed
• IL-1 and anti-inflammatory drugs modulate A beta cytotoxicity in PC12 cells Brain Res. 1996 Jun 03; 723(1-2):231-4. . View in PubMed
• Transferrin receptor-independent uptake of differic transferrin by human hepatoma cells with antisense inhibition of receptor expression Hepatology. 1996 Jun; 23(6):1512-20. . View in PubMed
• Inflammation and Alzheimer disease Mol Chem Neuropathol. 1996 May-Aug; 28(1-3):83-8. . View in PubMed
• Informatics and Geriatric Psychiatry Am J Geriatr Psychiatry. 1996 Spring; 4(2):140-151. . View in PubMed
• Antinuclear antibodies in multiple sclerosis Neurology. 1995 Dec; 45(12):2299-300;author reply 2300-1. . View in PubMed
• Iron release from recombinant N-lobe and mutants of human transferrin Biochemistry. 1995 Nov 07; 34(44):14428-34. . View in PubMed
• Uptake of iron from N-terminal half-transferrin by isolated rat hepatocytesEvidence of transferrin-receptor-independent iron uptake. Eur J Biochem. 1995 Aug 15; 232(1):129-33. . View in PubMed
• Cryptococcus neoformans melanin and virulence: mechanism of action Infect Immun. 1995 Aug; 63(8):3131-6. . View in PubMed
• A pilot study of clonidine plus physostigmine in Alzheimer’s disease Dementia. 1994 Sep-Oct; 5(5):243-6. . View in PubMed
• Shoulder-hand syndrome in cervical spinal cord injury Paraplegia. 1994 Sep; 32(9):588-92. . View in PubMed
• Inflammatory mechanisms in Alzheimer’s disease: implications for therapy Am J Psychiatry. 1994 Aug; 151(8):1105-13. . View in PubMed
• Primary receptor-recognition site of human transferrin is in the C-terminal lobe J Biol Chem. 1994 Mar 11; 269(10):7110-4. . View in PubMed
• The transferrin receptor and the release of iron from transferrin Adv Exp Med Biol. 1994; 356:31-40. . View in PubMed
• Determinants of Length of Stay in Geropsychiatry Am J Geriatr Psychiatry. 1994 Spring; 2(2):165-168. . View in PubMed
• The anion requirement for iron release from transferrin is preserved in the receptor-transferrin complex Biochemistry. 1993 Aug 17; 32(32):8162-7. . View in PubMed
• Response to Combination Cholinergic/Noradrenergic Treatments in a Patient With Alzheimer’s Disease Am J Geriatr Psychiatry. 1993 Summer; 1(3):244-248. . View in PubMed
• A pilot study of oral physostigmine plus yohimbine in patients with Alzheimer disease Alzheimer Dis Assoc Disord. 1993; 7(2):98-104. . View in PubMed
• Antisense suppression of transferrin receptor gene expression in a human hepatoma cell (HuH-7) line Am J Hematol. 1993 Jan; 42(1):74-80. . View in PubMed
• Continuous wave electron nuclear double resonance spectroscopy Methods Enzymol. 1993; 227:190-231. . View in PubMed
• Trazodone for Behavioral Disturbance in Alzheimer’s Disease Am J Geriatr Psychiatry. 1993 Autumn; 1(4):349-350. . View in PubMed
• Catalysis of the Haber-Weiss reaction by iron-diethylenetriaminepentaacetate J Inorg Biochem. 1992 Dec; 48(4):241-9. . View in PubMed
• Neuroleptic malignant syndrome induced by low-dose haloperidol Am J Psychiatry. 1992 Jun; 149(6):844. . View in PubMed
• Receptor-induced switch in site-site cooperativity during iron release by transferrin Biochemistry. 1992 Apr 28; 31(16):3963-7. . View in PubMed
• Entry of iron into cells: a new role for the transferrin receptor in modulating iron release from transferrin Ann Neurol. 1992; 32 Suppl:S62-8. . View in PubMed
• GPSYCH: Clinical management software for a Geropsychiatry Division Proc Annu Symp Comput Appl Med Care. 1992; 322-6. . View in PubMed
• Receptor-modulated iron release from transferrin: differential effects on N- and C-terminal sites Biochemistry. 1991 Oct 15; 30(41):9947-52. . View in PubMed
• A new role for the transferrin receptor in the release of iron from transferrin Biochemistry. 1991 Jan 15; 30(2):324-8. . View in PubMed
• Ferritin receptors and the role of ferritin in iron transport Targeted Diagn Ther. 1991; 4:339-54. . View in PubMed
• Medical evaluation of the elderly psychiatric patient Mt Sinai J Med. 1991 Jan; 58(1):85-90. . View in PubMed
• Evidence for functional differences between the two sites of rabbit transferrin: effects of serum and carbon dioxide Biochim Biophys Acta. 1990 Apr 09; 1052(1):24-8. . View in PubMed
• Release of iron from diferric transferrin in the presence of rat liver plasma membranes: no evidence of a plasma membrane diferric transferrin reductase Biochim Biophys Acta. 1990 Apr 09; 1052(1):29-35. . View in PubMed
• Iron toxicosis Int Rev Exp Pathol. 1990; 31:1-46. . View in PubMed
• Subcellular localization of ferritin and iron taken up by rat hepatocytes Biochem J. 1989 Sep 01; 262(2):685-8. . View in PubMed
• Hypochondriasis in the elderly depressed J Am Geriatr Soc. 1989 Jun; 37(6):507-10. . View in PubMed
• Microbial glycolipids: possible virulence factors that scavenge oxygen radicals Proc Natl Acad Sci U S A. 1989 Apr; 86(7):2453-7. . View in PubMed
• Pathways in the binding and uptake of ferritin by hepatocytes Biochim Biophys Acta. 1989 Mar 28; 1011(1):40-5. . View in PubMed
• Uptake of ferritin and iron bound to ferritin by rat hepatocytes: modulation by apotransferrin, iron chelators and chloroquine Biochim Biophys Acta. 1989 Feb 09; 1010(2):204-9. . View in PubMed
• Occult aspiration of a nut in an elderly patient: a case report Am J Forensic Med Pathol. 1988 Jun; 9(2):163-5. . View in PubMed
• The binding of molybdate to uteroferrinHyperfine interactions of the binuclear center with 95Mo, 1H, and 2H. J Biol Chem. 1988 Apr 25; 263(12):5757-63. . View in PubMed
• Interactions between isolated hepatocytes and Kupffer cells in iron metabolism: a possible role for ferritin as an iron carrier protein Hepatology. 1988 Mar-Apr; 8(2):296-301. . View in PubMed
• Spectroscopic and thermodynamic studies on the binding of gadolinium(III) to human serum transferrin Biochemistry. 1988 Feb 09; 27(3):1075-80. . View in PubMed
• Iron metabolism in the erythrophagocytosing Kupffer cell Hepatology. 1988 Jan-Feb; 8(1):32-8. . View in PubMed
• Iron metabolism in isolated liver cells Ann N Y Acad Sci. 1988; 526:93-100. . View in PubMed
• Detection of malignant tumors: water-suppressed proton nuclear magnetic resonance spectroscopy of plasma Magn Reson Med. 1987 Oct; 5(4):395-7. . View in PubMed
• Interaction of transferrin with iron-loaded rat peritoneal macrophages Br J Haematol. 1986 Feb; 62(2):275-86. . View in PubMed
• The novel “g’ = 174” EPR spectrum of pink and purple uteroferrin. J Biol Chem. 1980 Dec 10; 255(23):11204-9. . View in PubMed
• EPR and other studies of the anion-binding sites of transferrin Ann N Y Acad Sci. 1973 Dec 31; 222:337-46. . View in PubMed
• Citrate-mediated exchange of FE3+ among tranferrin molecules Biochem Biophys Res Commun. 1968 Jul 26; 32(2):220-6. . View in PubMed
• The stability constants of the Fe3+ conalbumin complexes Biochem Biophys Res Commun. 1968 Feb 26; 30(4):407-13. . View in PubMed
• A rapid screening test for deficiency of plasma ceruloplasmin and its value in the diagnosis of Wilson’s disease Am J Med. 1960 Apr; 28:550-4. . View in PubMed

• Schneider, Lon
• Thompson, Paul
• Zlokovic, Berislav
• Toga, Arthur
• Ringman, John
• Chui, Helena
• Rafii, Michael
• Rissman, Robert
• Donohue, Michael